Fibrosis Progression in Nonalcoholic Fatty Liver vs Nonalcoholic Steatohepatitis: A Systematic Review and Meta-analysis of Paired-Biopsy Studies

Clinical Gastroenterology and Hepatology

Volumn 13, Issue 4, 2015, Pages 643-654.e9

  Singh, Siddharth ^a   Allen, Alina M ^a   Wang, Zhen ^a   Prokop, Larry J ^a   Murad, Mohammad H ^a   Loomba, Rohit ^b  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cirrhosis; Fatty Liver; Fibrosis; Natural History; Nonalcoholic Steatohepatitis

Indexed keywords

COHORT ANALYSIS; DATA BASE; DISEASE COURSE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LIVER BIOPSY; LIVER FIBROSIS; META ANALYSIS; NONALCOHOLIC FATTY LIVER; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; STAGING; SYSTEMATIC REVIEW; BIOPSY; COMPARATIVE STUDY; COMPLICATION; CYTOCHEMISTRY; LIVER CIRRHOSIS; PATHOLOGY; RISK FACTOR;

BIOPSY; DISEASE PROGRESSION; HISTOCYTOCHEMISTRY; HUMANS; LIVER CIRRHOSIS; NON-ALCOHOLIC FATTY LIVER DISEASE; RISK FACTORS;

EID: 84924938800     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2014.04.014     Document Type: Review

References (50)

1. Anstee Q.M., Targher G., Day C.P. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 2013, 10:330-344.
2. Chalasani N., Younossi Z., Lavine J.E., et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012, 55:2005-2023.
3. Paredes A.H., Torres D.M., Harrison S.A. Nonalcoholic fatty liver disease. Clin Liver Dis 2012, 16:397-419.
4. Adams L.A., Harmsen S., St Sauver J.L., et al. Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study. Am J Gastroenterol 2010, 105:1567-1573.
5. Soderberg C., Stal P., Askling J., et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010, 51:595-602.
6. Loomba R., Sanyal A.J. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol 2013, 10:686-690.
7. Adams L.A., Sanderson S., Lindor K.D., et al. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. JHepatol 2005, 42:132-138.
8. Ekstedt M., Franzen L.E., Mathiesen U.L., et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006, 44:865-873.
9. Loomba R., Wesley R., Pucino F., et al. Placebo in nonalcoholic steatohepatitis: insight into natural history and implications forfuture clinical trials. Clin Gastroenterol Hepatol 2008, 6:1243-1248.
10. Matteoni C.A., Younossi Z.M., Gramlich T., et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999, 116:1413-1419.
11. Argo C.K., Northup P.G., Al-Osaimi A.M., et al. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. JHepatol 2009, 51:371-379.
12. Teli M.R., James O.F., Burt A.D., et al. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 1995, 22:1714-1719.
13. Pais R., Charlotte F., Fedchuk L., et al. Asystematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. JHepatol 2013, 59:550-556.
14. Moher D., Liberati A., Tetzlaff J., et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009, 151:264-269. W64.
15. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses.2012.
16. Ghany M.G., Kleiner D.E., Alter H., et al. Progression of fibrosis in chronic hepatitis C. Gastroenterology 2003, 124:97-104.
17. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
18. Higgins J.P., Thompson S.G., Deeks J.J., et al. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
19. Guyatt G.H., Oxman A.D., Kunz R., et al. GRADE guidelines: 7. Rating the quality of evidence-inconsistency. JClin Epidemiol 2011, 64:1294-1302.
20. Easterbrook P.J., Berlin J.A., Gopalan R., et al. Publication bias in clinical research. Lancet 1991, 337:867-872.
21. Egger M., Davey Smith G., Schneider M., et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
22. Argo C.K., Iezzoni J.C., Al-Osaimi A.M., et al. Thiazolidinediones for the treatment in NASH: sustained benefit after drug discontinuation?. JClin Gastroenterol 2009, 43:565-568.
23. Evans C.D., Oien K.A., MacSween R.N., et al. Non-alcoholic steatohepatitis: a common cause of progressive chronic liver injury?. JClin Pathol 2002, 55:689-692.
24. Fassio E., Alvarez E., Dominguez N., et al. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology 2004, 40:820-826.
25. Hamaguchi E., Takamura T., Sakurai M., et al. Histological course of nonalcoholic fatty liver disease in Japanese patients: tight glycemic control, rather than weight reduction, ameliorates liver fibrosis. Diabetes Care 2010, 33:284-286.
26. Hui A.Y., Wong V.W., Chan H.L., et al. Histological progression of non-alcoholic fatty liver disease in Chinese patients. Aliment Pharmacol Ther 2005, 21:407-413.
27. Ratziu V., Giral P., Charlotte F., et al. Liver fibrosis in overweight patients. Gastroenterology 2000, 118:1117-1123.
28. Wong V.W., Wong G.L., Choi P.C., et al. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut 2010, 59:969-974.
29. Abdelmalek M.F., Sanderson S.O., Angulo P., et al. Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial. Hepatology 2009, 50:1818-1826.
30. Shields W.W., Thompson K.E., Grice G.A., et al. The effect of metformin and standard therapy versus standard therapy alone in nondiabetic patients with insulin resistance and nonalcoholic steatohepatitis (NASH): a pilot trial. Therap Adv Gastroenterol 2009, 2:157-163.
31. Aithal G.P., Thomas J.A., Kaye P.V., et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 2008, 135:1176-1184.
32. Van Wagner L.B., Koppe S.W., Brunt E.M., et al. Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial. Ann Hepatol 2011, 10:277-286.
33. Sanyal A.J., Chalasani N., Kowdley K.V., et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. NEngl J Med 2010, 362:1675-1685.
34. Ratziu V., Charlotte F., Bernhardt C., et al. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology 2010, 51:445-453.
35. Brunt E.M., Janney C.G., Di Bisceglie A.M., et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999, 94:2467-2474.
36. Sterne J.A., Sutton A.J., Ioannidis J.P., et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 2011, 343:d4002.
37. Wree A., Broderick L., Canbay A., et al. From NAFLD to NASH to cirrhosis-new insights into disease mechanisms. Nat Rev Gastroenterol Hepatol 2013, 10:627-636.
38. Loomba R., Rao F., Zhang L., et al. Genetic covariance between gamma-glutamyl transpeptidase and fatty liver risk factors: role of beta2-adrenergic receptor genetic variation in twins. Gastroenterology 2010, 139:836-845.
39. Stinton L., Loomba R. Commentary: dissecting the PNPLA3 association with liver fat and stiffness, and interaction with diet. Aliment Pharmacol Ther 2014, 39:894-895.
40. Promrat K., Kleiner D.E., Niemeier H.M., et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010, 51:121-129.
41. Rafiq N., Bai C., Fang Y., et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol 2009, 7:234-238.
42. Loomba R., Abraham M., Unalp A., et al. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology 2012, 56:943-951.
43. Angulo P., Hui J.M., Marchesini G., et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007, 45:846-854.
44. Harrison S.A., Oliver D., Arnold H.L., et al. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008, 57:1441-1447.
45. Noureddin M., Yates K.P., Vaughn I.A., et al. Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients. Hepatology 2013, 58:1644-1654.
46. Huang H., Shiffman M.L., Cheung R.C., et al. Identification of two gene variants associated with risk of advanced fibrosis in patients with chronic hepatitis C. Gastroenterology 2006, 130:1679-1687.
47. Paris A.J., Snapir Z., Christopherson C.D., et al. Apolymorphism that delays fibrosis in hepatitis C promotes alternative splicing of AZIN1, reducing fibrogenesis. Hepatology 2011, 54:2198-2207.
48. Patin E., Kutalik Z., Guergnon J., et al. Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection. Gastroenterology 2012, 143:1244-1252.
49. Poynard T., Ratziu V., Charlotte F., et al. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. JHepatol 2001, 34:730-739.
50. Harrison S.A., Torgerson S., Hayashi P.H. The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am J Gastroenterol 2003, 98:2042-2047.